Old Web
English
Sign In
Acemap
>
authorDetail
>
Magdalena Wrona
Magdalena Wrona
AstraZeneca
Durvalumab
Head and neck squamous-cell carcinoma
Pathology
Medicine
Oncology
2
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
2020
Journal of Clinical Oncology
Weimin Li
Athena Matakidou
Zara Ghazoui
Han Si
Sophie Wildsmith
Nassim Morsli
Helen Mann
Magdalena Wrona
Melissa de los Reyes
Rajiv Raja
Craig Barker
Jessica Whiteley
Qu Zhang
Jérôme Fayette
Dan P. Zandberg
Ricard Mesia
Lillian L. Siu
Show All
Source
Cite
Save
Citations (3)
Correlation of angiogenic and immunomodulatory proteins with clinical outcomes of durvalumab (anti-PDL1) in recurrent/metastatic head and neck squamous cell carcinoma.
2019
Journal of Clinical Oncology
Xiang Guo
Brandon W. Higgs
Paul Baverel
Jean Fan
Nassim Morsli
Magdalena Wrona
Alejandro Javier Yovine
Shao-Chun Chang
Rosalin Arends
Lorin Roskos
Show All
Source
Cite
Save
Citations (0)
1